Biotech
Alnylam Pharmaceuticals, Inc.
1
Articles
Partner
Top Role
Apr 11, 2026
First Mention
Apr 11, 2026
Last Mention
1.25
Relevance Score
Coverage Timeline
April 2026
Regeneron and Alnylam’s $800M Bet: The Real Economics Behind Cardiovascular RNAi’s Next Blockbuster
The Week
Partner
Apr 11, 2026
The Regeneron/Alnylam partnership has unambiguously raised the ante for what late-stage, non-rare RNAi assets are worth.